The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

Clinical Lipidology

Volumn 8, Issue 1, 2013, Pages 13-41

  Catapano, Alberico ^a,b   Toth, Peter P ^c,d   Tomassini, Joanne E ^e   Tershakovec, Andrew M ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c CGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

aortic valve stenosis; chronic kidney disease; ezetimibe; familial hypercholesterolemia; LDL cholesterol; lipid; metabolic syndrome; statin; Type 2 diabetes

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE CORONARY SYNDROME; ADD ON THERAPY; AGE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AORTA STENOSIS; ARTICLE; BILIARY COLIC; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLANGITIS; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COLITIS; COLON POLYP; CONSTIPATION; DEMOGRAPHY; DENTAL CARIES; DERMATITIS; DIARRHEA; DIVERTICULOSIS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENITIS; DYSLIPIDEMIA; DYSPEPSIA; DYSPHAGIA; ECZEMA; EOSINOPHILIA; ERYTHEMA; ESOPHAGUS STENOSIS; FACE EDEMA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FECES; FLATULENCE; FOOD POISONING; GALLBLADDER DISEASE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; GINGIVA PAIN; HEMORRHOID; HEPATITIS; HEPATOMEGALY; HIATUS HERNIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER CYST; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTAL DISEASE; PERIORBITAL EDEMA; PHOTODERMATOSIS; PHOTOSENSITIVITY DISORDER; PIGMENT DISORDER; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PRURITUS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RHABDOMYOLYSIS; RISK MANAGEMENT; RISK REDUCTION; ROSACEA; SEX DIFFERENCE; SIDE EFFECT; SITOSTEROLEMIA; SKIN DEFECT; SKIN DISEASE; SKIN EXFOLIATION; SKIN TOXICITY; SUBCUTANEOUS NODULE; SYSTEMIC LUPUS ERYTHEMATOSUS; TOOTH DISEASE; TOOTH PAIN; URTICARIA; VALVULAR HEART DISEASE; VOMITING;

EID: 84873478245     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.88     Document Type: Article

References (172)

1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010
2. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) Collaborators efficacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005
3. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46(10), 1855-1862 (2005
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002
5. Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult Y 2009 recommendations. Can. J. Cardiol. 25(10), 567-579 (2009
6. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44(3), 720-732 (2004
7. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363-2372 (2006
8. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3-46 (2011
9. Foody JM, Sajjan SG, Hu XH et al. Loss of early gains in low-Density lipoprotein cholesterol goal attainment among high-risk patients. J. Clin. Lipidol. 4(2), 126-132 (2010
10. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-Density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am. Heart J. 154(3), 554-560 (2007
11. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr. Opin. Lipidol. 15(4), 387-392 (2004
12. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 10(6), 555-561 (2008
13. Cooper A, Nherera L, Calvert N et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, UK (2008
14. Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: Summary of NICE guidance. BMJ 336(7655), 1246-1248 (2008
15. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 223(1), 1-68 (2012
16. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31(4), 811-822 (2008
17. Mosca L, Benjamin EJ, Berra K et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women Y 2011 update: A guideline from the American Heart Association. J. Am. Coll. Cardiol. 57(12), 1404-1423 (2011
18. National Institute for Health and Clinical Excellence. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults and Children with Familial Hypercholesterolaemia. National Institute for Health and Clinical Excellence, U.K.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am. J. Kidney Dis. 41(SUPPL3), S1-S92 (2003
20. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(SUPPL3), S18-S29 (2011
21. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics Y 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), e21-e181 (2009
22. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-Analysis. J. Am. Coll. Cardiol. 51(1), 37-45 (2008
23. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: A meta-Analysis. J. Gerontol. A Biol. Sci. Med. Sci. 62(8), 879-887 (2007
24. Cournot M, Cambou JP, Quentzel S, Danchin N. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. Int. J. Cardiol. 111(1), 12-18 (2006
25. Jellinger PS, Smith DA, Mehta AE et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. 18(SUPPL1), 1-78 (2012
26. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106(8), 1024-1028 (2002
27. Zocor® (simvastatin), prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012
28. Mevacor® (lovastatin), prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012
29. Lipitor®, prescribing information. Pfizer, NY, USA (2012
30. Chen YC, Chen YD, Li X et al. The HMG-CoA reductase gene and lipid and lipoprotein levels: The multi-ethnic study of atherosclerosis. Lipids 44(8), 733-743 (2009
31. Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in AfricanYAmerican patients in a six-week trial. Am. J. Cardiol. 97(2), 229-235 (2006
32. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-Methylglutaryl coenzyme a reductase gene is associated with racial differences in low-Density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537-1544 (2008
33. Simon JA, Lin F, Hulley SB et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: The Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol. 97(6), 843-850 (2006
34. Standards of medical care in diabetes Y 2012. Diabetes Care 35(SUPPL1), S11-S63 (2012
35. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome Y Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Ciculation 109, 433-438 (2004
36. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109(4), 551-556 (2004
37. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005
38. Grundy SM. Low-Density lipoprotein, non-high-Density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106(20), 2526-2529 (2002
39. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(SUPPL3), S1-S8 (2011
40. Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler. SUPPL12(2), 221-263 (2011
41. Stefanutti C, Morozzi C, Di Giacomo S. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Curr. Med. Chem. 19(28), 4861-4868 (2012
42. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255-2267 (2011
43. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J. Am. Soc. Nephrol. 16(2), 489-495 (2005
44. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 80(1), 17-28 (2011
45. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non-high-Density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6(5), 1112-1120 (2011
46. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease. Contrib. Nephrol. 171, 135-142 (2011
47. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: A meta-Analysis. Int. J. Cardiol. pii: S0167-5273(12)00621-3 (2012
48. Wu Y, Wang Y, An C et al. Effects of rosuvastatin and atorvastatin on renal function: Meta-Analysis. Circ. J. 76(5), 1259-1266 (2012
49. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 21(5), 1220-1225 (1993
50. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. J. Am. Coll. Cardiol. 29(3), 630-634 (1997
51. Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 48(3), e1-e148 (2006
52. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 28(2), 230-268 (2007
53. Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: Does intervention work? Curr. Opin. Cardiol. 25(4), 379-384 (2010
54. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359(9312), 1125-1126 (2002
55. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-Converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110(10), 1291-1295 (2004
56. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104(18), 2205-2209 (2001
57. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389-2397 (2005
58. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343-1356 (2008
59. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306-U247 (2010
60. Davis HR Jr, Tershakovec AM, Tomassini JE, Musliner T. Intestinal sterol transporters and cholesterol absorption inhibition. Curr. Opin. Lipidol. 22(6), 467-478 (2011
61. Toth PP, Catapano A, Tomassini JE, Tershakovec AM. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. 5(5), 655-684 (2010
62. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: Cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6(4), 447-470 (2008
63. Tang W, Jia L, Ma Y et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochim. Biophys. Acta 1811(9), 549-555 (2011
64. Temel RE, Tang W, Ma Y et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest 117(7), 1968-1978 (2007
65. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-Term simvastatin treatment in coronary patients: Relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20(5), 1340-1346 (2000
66. Nissinen MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of non-Cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr. Metab. Cardiovasc. Dis. 20(5), 308-316 (2010
67. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-Statin therapies on non-Cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24(1), 249-259 (2008
68. Jakulj L, Vissers MN, Groen AK et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: A post-hoc analysis of the ENHANCE trial. J. Lipid Res. 51(4), 755-762 (2010
69. Lakoski SG, Xu F, Vega GL et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95(2), 800-809 (2010
70. Vytorin®, precribing information. Merck Sharp & Dohme Corp., NJ, USA (2012
71. Zetia®, prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012
72. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125-2134 (2002
73. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 91(4), 418-424 (2003
74. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur. Heart J. 24(8), 717-728 (2003
75. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 107(19), 2409-2415 (2003
76. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-Controlled trial. Mayo Clin. Proc. 79(5), 620-629 (2004
77. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-Controlled, factorial design study to evaluate the lipid-Altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26(11), 1758-1773 (2004
78. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-Administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487-1494 (2004
79. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-Comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 149(3), 464-473 (2005
80. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-Altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22(10), 2041-2053 (2006
81. Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-Density lipoprotein cholesterol goals. Am. J. Cardiol. 93(12), 1481-1486 (2004
82. Rodney RA, Sugimoto D, Wagman B et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in AfricanYAmerican patients with primary hypercholesterolemia. J. Natl Med. Assoc. 98(5), 772-778 (2006
83. Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin. Proc. 81(12), 1579-1588 (2006
84. Robinson JG, Ballantyne CM, Grundy SM et al. Lipid-Altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am. J. Cardiol. 103(12), 1694-1702 (2009
85. Foody JM, Brown WV, Zieve F et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am. J. Cardiol. 106(9), 1255-1263 (2010
86. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084-1091 (2002
87. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 80(5), 587-595 (2005
88. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. 21(4), 571-578 (2005
89. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-Administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. 102(2), 327-332 (2005
90. Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R. Efficacy and safety of ezetimibe co-Administered with ongoing atorvastatin therapy in achieving low-Density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. 59(6), 619-627 (2005
91. Dobs AS, Guyton JR, McClusky D et al. Coadministration of ezetimibe with simvastatin. J. Am. Coll. Cardiol. 41, 227A (2003
92. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-Administered with atorvastatin. Am. Heart J. 148(3), 447-455 (2004
93. Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co-Administered with simvastatin in thiazolidinedione-Treated Type 2 diabetic patients. Diabetes Obes. Metab. 7(1), 88-97 (2005
94. Conard SE, Bays HE, Leiter LA et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. 102(11), 1489-1494 (2008
95. Leiter LA, Bays H, Conard S et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. 102(11), 1495-1501 (2008
96. Zieve F, Wenger NK, Ben Yehuda O et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the zetia in the elderly [ZETELD] study). Am. J. Cardiol. 105(5), 656-663 (2010
97. Reckless JP, Henry P, Pomykaj T et al. Lipid-Altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: The INFORCE study. Int. J. Clin. Pract. 62(4), 539-554 (2008
98. Bays HE, Davidson MH, Massaad R et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-Titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 108(4), 523-530 (2011
99. Barrios V, Amabile N, Paganelli F et al. Lipid-Altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared with doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. 59(12), 1377-1386 (2005
100. Constance C, Westphal S, Chung N et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 9(4), 575-584 (2007
101. Farnier M, Averna M, Missault L et al. Lipid-Altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy Y The IN-CROSS study. Int. J. Clin. Pract. 63(4), 547-559 (2009
102. Hing Ling PK, Civeira F, Dan AG et al. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: A randomized, double-blind, active-Controlled, multicenter study. Lipids Health Dis. 11, 18 (2012
103. Rosen JB, Jimenez JG, Pirags V et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab. Vasc. Dis. Res. doi:10.1177/1479164112465212 (2013) (Epub ahead of print
104. Bays H. Ezetimibe. Expert Opin. Investig. Drugs 11(11), 1587-1604 (2002
105. Morrone D, Weintraub WS, Toth PP et al. Lipid-Altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223(2), 251-261 (2012
106. Zieve F, Brown WV, Foody JM et al. Attainment of dual treatment levels for hsCRP and lipids in older (=65) patients with CVD risk: Ezetimibe/ simvastatin vs atorvastatin. J. Clin. Lipidol. 5, 3 (2010
107. Ben Yehuda O, Wenger NK, Constance C et al. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. J. Geriatr. Cardiol. 8(1), 1-11 (2011
108. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-Density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-Controlled trial. Am. J. Geriatr. Pharmacother. 3(4), 218-228 (2005
109. Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-Titration in patients at moderately high or high risk for coronary heart disease. Int. J. Cardiol. 153(2), 141-147 (2011
110. Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and ezetimibe+statin therapy in patients aged <65, 65-74, and 75 years and older. Aging Health 3(6), 691-705 (2007
111. Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21(15), 1025-1032 (2004
112. Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM. Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis. 10, 146 (2011
113. Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J. Womens Health (Larchmt) 13(10), 1101-1107 (2004
114. Ose L, Shah A, Davies MJ et al. Consistency of lipid-Altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: Results of a pooled retrospective analysis. Curr. Med. Res. Opin. 22(5), 823-835 (2006
115. Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-Controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 58(8), 746-755 (2004
116. Pearson TA, Denke MA, McBride PE et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-Density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: A substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin. Proc. 81(9), 1177-1185 (2006
117. Goldberg RB, Guyton JR, Mazzone T et al. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with Type 2 diabetes and hypercholesterolemia. Diabetes Care 33(5), 1021-1024 (2010
118. Weinstock RS, Goldberg RB, Guyton JR et al. Effect of ezetimibe/simvastatin on lowering levels of LDL-C and non-HDL-C, apoB, and hs-CRP in patients with Type 2 diabetes. J. Clin. Lipidol. 2(1), 25-35 (2008
119. Abate N, Catapano AL, Ballantyne CM et al. Effect of ezetimibe/ simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J. Clin. Lipidol. 2(2), 91-105 (2008
120. Conard S, Bays H, Leiter LA et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes. Metab. 12(3), 210-218 (2010
121. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res. 3(2), 93-102 (2006
122. Simons L, Tonkon M, Masana L et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. 20(9), 1437-1445 (2004
123. Leiter LA, Betteridge DJ, Farnier M et al. Lipid-Altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: An analysis of pooled data from 27 clinical trials. Diabetes Obes. Metab. 13(7), 615-628 (2011
124. Guyton JR, Betteridge DJ, Farnier M et al. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diab. Vasc. Dis. Res. 8(2), 160-172 (2011
125. Averna M, Missault L, Vaverkova H et al. Lipid-Altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab. Vasc. Dis. Res. 8(4), 262-270 (2011
126. Feldman T, Ose L, Shah A et al. Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 5(1) 13-21 (2007
127. Robinson JG, Ballantyne CM, Hsueh W et al. Achievement of specified low-Density lipoprotein cholesterol, non-high-Density lipoprotein cholesterol apolipoprotein B, and high-Sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J. Clin. Lipidol. 5(6), 474-482 (2011
128. Farnier M, Freeman MW, MacDonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897-905 (2005
129. Fazio S, Guyton JR, Polis AB et al. Long-Term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am. J. Cardiol. 105(4), 487-494 (2010
130. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-Altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol. 51(16), 1564-1572 (2008
131. McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-Term co-Administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47(8), 1584-1587 (2006
132. Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795-797 (2004
133. Zema MJ. Add-on therapy for hypercholesterolemia: A pilot comparison of two gastrointestinally-Acting agents in statin-Treated patients. J. Clin. Lipidol. 3(2), 119-124 (2009
134. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469-2475 (2002
135. Yamamoto A, Harada-Shiba M, Endo M et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-Apheresis therapy. Atherosclerosis 186(1), 126-131 (2006
136. van der Graaf, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52(17), 1421-1429 (2008
137. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431-1443 (2008
138. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 357(9256), 577-581 (2001
139. Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intimaYmedia thickness: More clarity or confusion? J. Am. Coll. Cardiol. 52(25), 2206-2209 (2008
140. Toth PP, Maki KC. A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial: Should ezetimibe move to the "back of the line" as a therapy for dyslipidemia? J. Clin. Lipidol. 2(5), 313-317 (2008
141. Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356(16), 1620-1630 (2007
142. Simon T, Boutouyrie P, Gompel A et al. Rationale, design and methods of the CASHMERE study. Fundam. Clin. Pharmacol. 18(1), 131-138 (2004
143. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-Term safety and efficacy of high-Dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol. 95(2), 264-266 (2005
144. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52(25), 2198-2205 (2008
145. Califf RM, Lokhnygina Y, Cannon CP et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J. 159(5), 705-709 (2010
146. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010
147. Costanzo P, Perrone-Filardi P, Vassallo E et al. Does carotid intimaYmedia thickness regression predict reduction of cardiovascular events? A meta-Analysis of 41 randomized trials. J. Am. Coll. Cardiol. 56(24), 2006-2020 (2010
148. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intimaYmedia thickness. N. Engl. J. Med. 361(22), 2113-2122 (2009
149. Duivenvoorden R, Vergeer M, Kastelein JJ. Niacin compared with ezetimibe. N. Engl. J. Med. 362(11), 1046-1047 (2010
150. Salen G, von Bergmann K, Lutjohann D et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109(8), 966-971 (2004
151. Lutjohann D, von Bergmann K, Sirah W et al. Long-Term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: A 2year, open-label extension study. Int. J. Clin. Pract. 62(10), 1499-1510 (2008
152. Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130(6), 1853-1857 (2006
153. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. SUPPL84, S207-S210 (2003
154. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-Controlled trial. Lancet 377(9784), 2181-2192 (2011
155. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-Density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160(5), 785-794 (2010
156. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360(14), 1395-1407 (2009
157. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353(3), 238-248 (2005
158. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-Controlled trial. Lancet 361(9374), 2024-2031 (2003
159. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-Analysis of indivudual data from 27 randomised trials. Lancet 380(9841), 581-590 (2012
160. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-Controlled trial. Lancet 361(9374), 2005-2016 (2003
161. Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. 2, CD007784 (2009
162. Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: Meta-Analysis and meta-regression of randomised controlled trials. BMJ 336(7645), 645-651 (2008
163. Tonelli M, Keech A, Shepherd J et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 16(12), 3748-3754 (2005
164. Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol. 105(12), 1802-1808 (2010
165. Cannon CP, Guigliano RP, Blazing MA et al. Design and Rationale of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am. Heart J. 156(5), 826-832 (2008
166. Toth PP, Morrone D, Weintraub WS et al. Safety profile of statins alone or combined with ezetimibe: A pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. Int. J. Clin. Pract. 66(8), 800-812 (2012
167. Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am. J. Cardiol. 101(11), 1606-1613 (2008
168. Derosa G, D'Angelo A, Franzetti IG et al. Efficacy and safety of ezetimibe/simvastatin association on non-Diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J. Clin. Pharm. Ther. 34(3), 267-276 (2009
169. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy Y a genome wide study. N. Engl. J. Med. 359(8), 789-799 (2008
170. Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359(13), 1357-1366 (2008
171. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-Marketing analysis. J. Clin. Lipidol. 3(2), 138-142 (2009
172. Halleck M, Davis HR, Kirschmeier P et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 258(2-3), 116-130 (2009